This paper reviews data from clinical trials (PIONEER 1, 2, 3, and 7) comparing oral semaglutide (once-daily doses of 3, 7, or 14 mg) with either once-daily
Newsome et al
In PIONEER trials 1–3, oral semaglutide treatment was initiated at 3 mg once daily, with dose escalation every 4 weeks until the randomized dose was achieved [Citation 20, Citation 21, Citation 23]
At week 52, HbA 1c and body weight (trial product estimand) were significantly reduced versus empagliflozin
Methods: PIONEER 10 was an open-label, randomised, active-controlled, phase 3a trial done at 36 sites (clinics and university hospitals) in Japan
Subjects with T2DM were included if they were aged 50 years or older with established CV disease and/or CKD or if they were aged greater than 60 years with CV risk factors only
The PIONEER PLUS trial showed that in adults with type 2 diabetes mellitus already on an oral antihyperglycemic regimen, once-daily oral semaglutide 25 mg and 50 mg achieved greater reduction in HbA1c and body weight with a similar safety profile compared to 14 mg once daily
Pioneer Teens: This on-going trial would examine the efficacy, safety of semaglutide in 132 type 2 diabetic children, teenagers (aged 10–17 years) receiving daily-once oral semaglutide (with dose escalation to an individual maximum tolerated dose) or placebo
Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials The CV safety of semaglutide vs
Clinical studies have demonstrated that Rybelsus, with its active ingredient oral semaglutide, cаn effectively reduсe blood sugаr levels аnd promоte weight loss in individuals with type 2 diabetes
It is a once-daily tablet that belongs to the class of SGLT-2 inhibitors‚ whiсh work by blocking glucose reabsorption in the kidneys and promoting its excretion through urine
In PIONEER trials that studied oral semaglutide 3, 7, and 14 mg, the proportion of patients with gastrointestinal AEs and the proportion of patients who discontinued treatment due to gastrointestinal AEs appeared to increase with dose [46, 48, 53–55] (Table (Table4)